Effect of estrogen on lipid profile and fibrinolytic activity in streptozotocin-induced diabetic rats

ABSTRACT

To investigate the effect of estrogen on lipid profile and fibrinolytic activity in diabetic rats, 40 male albino rats were divided into 4 groups; [1] 10 control rats [2] 10 diabetic rats, where diabetes was induced by injection of streptozotocin 60 mg/kg sc. [bi. sugar was 300 +/- 11 mg%] [3] 10 normal rats injected sc by 17-beta estradiol depot 70 ng/kg; and [4] 10 diabetic rats injected by 17- beta estradiol after diabetes has been well established. After one month rats were killed by decapitation and the collected blood samples were tested for fasting blood glucose level, lipid profile and plasminogen activator inhibitor type- 1 [PAI- 1] and tissue plasminogen activator [t-PA] antigens [for fibrinolytic activity] in normal and diabetic rats. 17- beta estradiol improved sign fasting blood glucose level, lipid profile [decreased triglycerides, total cholesterol and low density lipoprotein with increased high density lipoprotein. levels]. Levels of PAT-I-1 and t-PA were significantly decreased by 17- beta estradiol in diabetic rats, while PM-I was significantly decreased and t-PA showed in change in nor mal rats received 17- beta estradiol. In conclusion 1 7- estradiol improves fasting blood glucose, lipid profile and fibririolytic activity in normal and streptozotocin-induced diabetic rats. Estrogen hormone replacement therapy should be considered in postmenopausal women to protect them from cardiovascular risks or at least to ameliorate and delay of its morbidity and mortality if already present